HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Allyson Masci Selected Research

PI 2301

5/2011Safety, pharmacokinetic, and pharmacodynamic evaluations of PI-2301, a potent immunomodulator, in a first-in-human, single-ascending-dose study in healthy volunteers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Allyson Masci Research Topics

Disease

2Dry Eye Syndromes (Dry Eye Syndrome)
05/2018 - 03/2013
1Rheumatoid Arthritis
03/2013
1Cryopyrin-Associated Periodic Syndromes
03/2013
1Injection Site Reaction
05/2011
1Autoimmune Diseases (Autoimmune Disease)
05/2011
1Multiple Sclerosis
01/2011
1Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
01/2011

Drug/Important Bio-Agent (IBA)

2Amino AcidsFDA Link
05/2011 - 01/2011
1InterleukinsIBA
05/2018
1Interleukin-1 (Interleukin 1)IBA
03/2013
1Immunologic Factors (Immunomodulators)IBA
05/2011
1PI 2301IBA
05/2011

Therapy/Procedure

1Subcutaneous Injections
05/2011